Drug Discovery & DDS– category –
-
Galmed Pioneers Cardiac-Targeted LNP for Fibrosis, Repurposing Aramchol with Precision
GlobeNewswire via Galmed Israel Overview Galmed, in collaboration with Barcode Nanotech, has engineered a novel lipid nanoparticle (LNP) formulation for its SCD1 inhibitor, Aramchol. This innovation enables precise, heart-targeted delive... -
Oregon State University Develops Novel Sugar-Coated Nanoparticle Therapy for Glioblastoma: Boosting Mouse Survival by 50%
Oregon State University via Medical Xpress USA Overview Researchers at Oregon State University have developed a new experimental glioblastoma treatment using sugar-coated nanoparticles to deliver genetic instructions that restore a tumor... -
Bora Biologics Expands US Biologics Manufacturing Capacity to 20,000 Liters with New Rockville, Maryland Site
PharmaSource USA Overview Bora Biologics has expanded its U.S. drug substance manufacturing platform by adding a new site in Rockville, Maryland. This expansion increases its single-use bioreactor capacity to 20,000 liters, with scalabil... -
Cytovance Biologics Enhances Biologics Manufacturing Process Development with Perfusion Capabilities to Boost Productivity
Cytovance Biologics USA Overview Cytovance Biologics, a CDMO, has expanded its upstream process development services by integrating perfusion capabilities. This technological addition enables higher productivity, extended cell culture du... -
Monte Rosa Therapeutics’ NEK7 Molecular Glue Degrader MRT-8102/8120 Shows 85% CRP Reduction in Cardiovascular Risk Patients in Positive Phase 1 Interim Data
AllMind AI News USA Overview Monte Rosa Therapeutics reported positive interim Phase 1 data for its NEK7-directed molecular glue degrader, MRT-8102/8120, demonstrating an 85% median reduction in C-reactive protein (CRP) over 4 weeks in c... -
Denali Therapeutics Announces Breakthroughs in Blood-Brain Barrier Biologic Delivery: AVLAYAH™ Receives FDA Accelerated Approval for Hunter Syndrome
Denali Therapeutics USA Overview Denali Therapeutics CEO Dr. Ryan Watts will deliver a plenary address at AAIC 2026, highlighting the company's breakthrough advancements in delivering biologic therapies across the blood-brain barrier (BB... -
GE HealthCare and Mayo Clinic Collaborate on Personalized Radioligand Therapy for Advanced Prostate Cancer: Launching MI-BET Study
GE HealthCare USA Overview GE HealthCare and Mayo Clinic have initiated the MI-BET study, a collaborative research effort to advance personalized radioligand therapy (RLT) for patients with advanced prostate cancer. This study will integ... -
FDA Grants Traditional Approval to Retevmo (selpercatinib) for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors, Expanding Patient Access
FDA USA Overview On July 14, 2026, the FDA granted traditional approval to Eli Lilly and Company's Retevmo (selpercatinib) for patients aged two years and older with locally advanced or metastatic RET fusion-positive solid tumors that ha... -
Pfizer and Arvinas’ Veppanu (vepdegestrant) Gains FDA Approval, Revolutionizing ESR1-Mutated Advanced Breast Cancer as First PROTAC
DCAT Value Chain Insights USA Overview In 2026, Pfizer and Arvinas' Veppanu (vepdegestrant) received FDA approval for advanced breast cancer with ESR1 mutations, becoming the first FDA-approved PROTAC. This drug offers a groundbreaking o... -
FDA Approves Celcuity’s Revtorpyk (gedatolisib) for HR-Positive, HER2-Negative Metastatic Breast Cancer in New Combination Regimen
FDA USA Overview On July 14, 2026, the FDA approved Celcuity Inc.'s Revtorpyk (gedatolisib) for adult patients with HR-positive/HER2-negative metastatic breast cancer without PIK3CA mutation. The drug is approved for use in combination w...
